Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio Receives Award from Cystic Fibrosis Foundation|
January 16, 2018
|Motif Bio to participate in panel discussion at upcoming Cantor Antibiotics Summit|
January 5, 2018
|Motif Bio REVIVE-1 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Clinical Infectious Diseases|
December 21, 2017